Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma


Disclosures: CT receive honorarium and research funding from BeiGene. NH, YL, YG, XS and LW are employed by BeiGene.

Contributions: TF, CCT, KT, TN, NH, YL and YG performed experiments and analyzed data. DT and HXAY performed high dimensional analysis of the FACS-data. NH, LW, YL, YG and XS performed pre-clinical experiments on ibrutinib and zanubrutinib. PN and JT provided important intellectual input. IV and CT supervised the study and analysed data. SH, JS, AR, DR and RK included patients and/or processed and stored patient samples. TF, CT and IV co-wrote the manuscript; and all the authors contributed to its editing.